TABLE 5.
Tacrolimus concentrations and clinical outcomes at Month 3 post‐transplantation
| Yes | No | P‐value | |
|---|---|---|---|
| BPAR | (n = 14) | (n = 153) | |
| [Tac]blood (ng/ml) | 7.0 (4.9–8.3) | 7.7 (6.4–9.2) | 0.18 |
| [Tac]cells (pg/106 cells) | 24.8 (18.4–34.8) | 27.0 (19.0–37.0) | 0.54 |
| [Tac]cells/[Tac]blood | 3.8 (2.4–5.6) | 3.5 (2.4–4.9) | 0.67 |
| Nephrotoxicity | (n = 52) | (n = 123) | |
| [Tac]blood (ng/ml) | 7.3 (5.8–8.4) | 7.8 (6.2–9.2) | 0.38 |
| [Tac]cells (pg/106 cells) | 26.5 (20.3–33.6) | 27.0 (18.3–38.3) | 0.91 |
| [Tac]cells/[Tac]blood | 3.6 (2.7–5.4) | 3.5 (2.4–5.1) | 0.60 |
| PTDM | (n = 36) | (n = 139) | |
| [Tac]blood (ng/ml) | 7.0 (6.0–8.9) | 7.6 (6.2–9.2) | 0.26 |
| [Tac]cells (pg/106 cells) | 28.0 (20.1–38.8) | 26.5 (18.5–36.5) | 0.58 |
| [Tac]cells/[Tac]blood | 4.0 (2.7–5.9) | 3.5 (2.4–5.0) | 0.26 |
[Tac]cells indicates the unadjusted tacrolimus pre‐dose concentration in peripheral blood mononuclear cell concentration. [Tac]blood indicates the unadjusted tacrolimus pre‐dose whole blood concentration. Data is shown as median (IQR). P denotes the comparison by the Mann–Whitney U‐test. BPAR, biopsy‐proven acute rejection; PTDM, post‐transplant diabetes mellitus.